Senate Resolution 787 is a commemorative resolution recognizing Ehlers-Danlos Syndrome (EDS), a group of inherited connective tissue disorders that can affect the skin, joints, blood vessels, internal organs, and bones. The resolution describes common symptoms of EDS, including joint hypermobility, pain, easy bruising, digestive issues, dizziness, and complications involving the heart and other organs. It also notes that many people with EDS experience postural orthostatic tachycardia syndrome (POTS), which can cause rapid heart rate changes and related symptoms such as fainting, fatigue, and cognitive difficulties.
The resolution states that EDS is likely underdiagnosed, can significantly reduce quality of life, and currently has no known cure. It emphasizes the importance of early and accurate diagnosis, medical planning, research, and public awareness. It also highlights the role of support groups in helping affected individuals and educating both the public and the health care community.
The measure formally declares May 2026 as Ehlers-Danlos Syndrome Awareness Month in Illinois. It does not amend the Illinois Compiled Statutes or create regulatory requirements; instead, it is a symbolic legislative action intended to raise awareness and encourage research and funding toward a cure.
The overall sentiment reflected in the resolution is strongly supportive and sympathetic toward people living with EDS. Because there are no recorded committee transcripts or votes, there is no evidence of opposition or debate in the available record. The tone of the measure is advocacy-oriented, focusing on recognition, education, and hope for improved diagnosis and treatment.
There is little apparent contention in the bill itself, since it is a nonbinding resolution. Any potential points of discussion would likely center on the value of state recognition, awareness campaigns, and encouraging research funding, rather than on legal or fiscal changes. The resolution is aimed at patients, families, medical providers, researchers, and support organizations connected to EDS and related dysautonomia conditions such as POTS.
SR0787 has no direct effect on Illinois statutes, agency rules, or legal rights and obligations. Its practical impact is to designate May 2026 as Ehlers-Danlos Syndrome Awareness Month and to use the Senate’s platform to promote awareness, education, and research support for EDS and related conditions such as POTS. The resolution may help affected individuals and advocacy groups by increasing visibility and encouraging the health care community and the public to recognize symptoms and seek earlier diagnosis.
The sentiment around the bill is positive and supportive. The resolution is framed as a tribute to people living with EDS and as an encouragement for research, funding, and public awareness. With no committee transcripts or recorded votes available, there is no indication of formal opposition, and the measure appears to be noncontroversial and widely sympathetic in tone.
No specific contention is evident in the available record. Because SR0787 is a ceremonial awareness resolution rather than a policy or spending bill, any disagreement would likely be limited to the general question of whether the legislature should issue awareness proclamations. The text itself does not present competing viewpoints, and there are no transcripts or votes showing objections from legislators, patients, or advocacy groups.